<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555486</url>
  </required_header>
  <id_info>
    <org_study_id>DCR-PHXC-104</org_study_id>
    <nct_id>NCT04555486</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients</brief_title>
  <acronym>PHYOX4</acronym>
  <official_title>A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dicerna Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dicerna Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological&#xD;
      parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants&#xD;
      should have had at least one stone event within 12 months of screening and intact renal&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential participants are screened over an up-to-35-day period (with an extra 7-day period&#xD;
      for participants who are required to repeat screening 24-hour urine collections or initially&#xD;
      unanalyzable screening laboratory assessment samples) prior to randomization. Eligible&#xD;
      participants will receive a single dose of DCR-PHXC or placebo on Day 1.&#xD;
&#xD;
      In order to maintain the treatment blind, 24-hour urine oxalate (Uox) results that could&#xD;
      unblind the study will not be reported to investigative sites or other blinded personnel&#xD;
      until the study has been unblinded.&#xD;
&#xD;
      It is expected that approximately 10 participants will be screened in order to randomize 6&#xD;
      participants (2:1 randomization; 4 nedosiran:2 placebo) to the study.&#xD;
&#xD;
      Following the up-to-6-week screening period, participants will return to the clinic for&#xD;
      interim visits up to Day 85. Visits occurring between the Day 1 and the Day 85 visit may be&#xD;
      conducted as at-home telemedicine visits at the discretion of the Investigator. The total&#xD;
      time on study for each participant is approximately 18 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Actual">September 7, 2021</completion_date>
  <primary_completion_date type="Actual">September 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomly assigned to one of two interventions: the study drug DCR-PHXC (also known as nedosiran) or the placebo comparator Sterile Normal Saline. For every 2 participants that receive DCR-PHXC, 1 participant will receive placebo. Thus, 4 participants are expected to receive DCR-PHXC, and 2 participants are expected to receive placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of a single dose of DCR-PHXC in PH3 Patients</measure>
    <time_frame>Screening through Day 85</time_frame>
    <description>Number of patients with abnormalities in clinically significant laboratory results, vital signs, and 12-lead ECG findings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics (PK) of a single dose of DCR-PHXC in PH3 patients</measure>
    <time_frame>Day 1 (dosing) through Day 29</time_frame>
    <description>Measure maximum plasma concentration of DCR-PHXC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants achieving a &gt; 30% decrease from baseline in 24-hour Urine Oxalate (Uox) on 2 consecutive visits</measure>
    <time_frame>After screening, 24-hour Uox will be measured at Days 29, 43, 57, and 85.</time_frame>
    <description>Participants must maintain at least a 30% decrease from the average of 2 screening 24-hour Uox values to be considered &quot;responders&quot; to treatment. The proportion of responders to non-responders will be utilize to assess the efficacy of a single dose of DCR-PHXC in PH3 patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Primary Hyperoxaluria Type 3</condition>
  <arm_group>
    <arm_group_label>DCR-PHXC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants that are at least 12 years old will receive a single dose of 3 mg/kg DCR-PHXC (or nedosiran) via subcutaneous (SC) injection. Participants that are 6-11 years old will receive a single dose of 3.5 mg/kg DCR-PHXC (nedosiran) via SC injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single dose of Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCR-PHXC</intervention_name>
    <description>Intervention, drug, DCR-PHXC</description>
    <arm_group_label>DCR-PHXC</arm_group_label>
    <other_name>Nedosiran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Genetically confirmed PH3&#xD;
&#xD;
          -  24-hour Uox excretion ≥ 0.7 mmol (adjusted per 1.73 m^2 body surface area [BSA] in&#xD;
             participants &lt; 18 years of age) on both assessments conducted in the screening period&#xD;
&#xD;
          -  Less than 20% variation between the two 24-hour urinary creatinine excretion values&#xD;
             (mmol/kg/24 hours) in the screening period&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) at screening ≥ 30 mL/min, normalized to&#xD;
             1.73 m^2 BSA&#xD;
&#xD;
          -  History of at least one stone event within the last 12 months. Stone events are&#xD;
             defined as any of the following:&#xD;
&#xD;
               -  renal stone requiring medical intervention, e.g., outpatient procedures such as&#xD;
                  lithotripsy, or hospitalization or inpatient surgical intervention for confirmed&#xD;
                  stone-related pain and/or complications;&#xD;
&#xD;
               -  stone passage with or without hematuria; or&#xD;
&#xD;
               -  renal colic requiring medication.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Documented evidence of clinical manifestations of systemic oxalosis (including&#xD;
             pre-existing retinal, heart, or skin calcifications, or history of severe bone pain,&#xD;
             pathological fractures, or bone deformations)&#xD;
&#xD;
          -  Plasma oxalate &gt; 30 μmol/L&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Haagensen, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Dicerna Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary hyperoxaluria</keyword>
  <keyword>primary hyperoxaluria type 3</keyword>
  <keyword>primary hyperoxaluria 3</keyword>
  <keyword>PH</keyword>
  <keyword>PH type 3</keyword>
  <keyword>PH3</keyword>
  <keyword>RNAi</keyword>
  <keyword>RNAi therapeutic</keyword>
  <keyword>LDHA</keyword>
  <keyword>LDH</keyword>
  <keyword>GalNAc</keyword>
  <keyword>siRNA</keyword>
  <keyword>nedosiran</keyword>
  <keyword>DCR-PHXC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

